Weimand BM, Solli KK, Reichelt WH, Tanum L. Enablers and hindrances for longer-term abstinence in opioid dependent individuals receiving treatment with extended-release naltrexone: a Norwegian longitudinal recovery trial (NaltRec study). Contemp Clin Trials Commun. 2021;21: 100728.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Tanum L, Solli KK, Latif ZE, Benth JS, Opheim A, Sharma-Haase K, et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiat. 2017;74(12):1197–205.

Article  Google Scholar 

Solli KK, Latif ZE, Opheim A, Krajci P, Sharma-Haase K, Benth JS, et al. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial. Addiction. 2018;113(10):1840–9.

PubMed  Article  Google Scholar 

Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309–18.

CAS  PubMed  Article  Google Scholar 

Leshner AI. Addiction is a brain disease, and it matters. Science. 1997;278(5335):45–7.

CAS  PubMed  Article  Google Scholar 

McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284(13):1689–95.

CAS  PubMed  Article  Google Scholar 

EMCDDA. European Drug Report: Trend and Developments. 2020. https://www.emcdda.europa.eu/publications/edr/trendsdevelopments/2020_en.

United Nations Office on Drugs and Crime, World Drug Report 2021 (United Nations publication, Sales No. E.21.XI.8).

Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018;113(7):1188–209.

PubMed  PubMed Central  Article  Google Scholar 

Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90–6.

PubMed  Article  Google Scholar 

Kober H. Emotion regulation in substance use disorders. Handbook of emotion regulation. 2nd ed. New York: The Guilford Press; 2014. p. 428–46.

Google Scholar 

Laudet AB. What does recovery mean to you? Lessons from the recovery experience for research and practice. J Subst Abuse Treat. 2007;33(3):243–56.

PubMed  PubMed Central  Article  Google Scholar 

Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-41, HHS Publication No. (SMA) 11–4658. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2011.

Dennis ML, Foss MA, Scott CK. An eight-year perspective on the relationship between the duration of abstinence and other aspects of recovery. Eval Rev. 2007;31(6):585–612.

PubMed  Article  Google Scholar 

Hser YI. Predicting long-term stable recovery from heroin addiction: findings from a 33-year follow-up study. J Addict Dis. 2007;26(1):51–60.

PubMed  Article  Google Scholar 

Hser YI, Evans E, Grella C, Ling W, Anglin D. Long-term course of opioid addiction. Harv Rev Psych. 2015;23(2):76–89.

Article  Google Scholar 

World Health Organization (WHO). Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organization; 2009.

Google Scholar 

Simoens S, Matheson C, Bond C, Inkster K, Ludbrook A. The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. Br J Gen Pract. 2005;55(511):139.

PubMed  PubMed Central  Google Scholar 

Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies–tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–6.

PubMed  Article  Google Scholar 

Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622-e.

PubMed  Article  Google Scholar 

Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014. https://doi.org/10.1002/14651858.CD002207 (pub4).

Article  PubMed  Google Scholar 

Zinöcker S, Shrestha M, Næss GE, Kornør H. Effekter av legemiddelassistert rehabilitering sammenliknet med ikke-medikamentell behandling av opioidavhengighet: En systematisk oversikt [Effects of opioid maintenance treatment versus no drug therapies for opioid dependence: A systematic review] Rapport−2020. Oslo: Folkehelseinstituttet, 2020.

Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31(3):207–25.

PubMed  PubMed Central  Article  Google Scholar 

Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;2009(3):Cd002209.

PubMed Central  Google Scholar 

Carlsen SL, Lunde LH, Torsheim T. Opioid and polydrug use among patients in opioid maintenance treatment. Subst Abuse Rehabil. 2020;11:9–18.

PubMed  PubMed Central  Article  Google Scholar 

Soyka M, Strehle J, Rehm J, Bühringer G, Wittchen HU. Six-year outcome of opioid maintenance treatment in heroin-dependent patients: results from a naturalistic study in a nationally representative sample. Eur Addict Res. 2017;23(2):97–105.

PubMed  Article  Google Scholar 

White WL, Campbell MD, Spencer RD, Hoffman HA, Crissman B, DuPont RL. Patterns of abstinence or continued drug use among methadone maintenance patients and their relation to treatment retention. J Psychoact Drugs. 2014;46(2):114–22.

Article  Google Scholar 

Witte TH, Jaiswal J, Mumba MN, Mugoya GCT. Stigma surrounding the use of medically assisted treatment for opioid use disorder. Subst Use Misuse. 2021;56(10):1467–75.

PubMed  Article  Google Scholar 

Steiro A, Hestevik CH, Shrestha M, Muller AE. Erfaringer blant pasienter og helseperso nell med legemiddelassistert rehabilitering (LAR): En systematisk oversikt over kvalitative studier. [Patients’ and healthcare personnel’s experiences with opioid maintenance treatment (OMT): A systematic review of qualitative studies] Rapport − 2020. Oslo: Folkehelseinstituttet, 2020.

Grønnestad TE, Sagvaag H. Stuck in limbo: illicit drug users’ experiences with opioid maintenance treatment and the relation to recovery. Int J Qual Stud Health Well Being. 2016;11(1):31992.

PubMed  Article  Google Scholar 

Granerud A, Toft H. Opioid dependency rehabilitation with the opioid maintenance treatment programme—a qualitative study from the clients’ perspective. Subst Abus Treat Prev Policy. 2015. https://doi.org/10.1186/s13011-015-0031-4.

Article  Google Scholar 

Tetrault JM, Fiellin DA. Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals. Drugs. 2012;72(2):217–28.

CAS  PubMed  PubMed Central  Article  Google Scholar 

McKeganey N, Bloor M, Robertson M, Neale J, MacDougall J. Abstinence and drug abuse treatment: results from the Drug Outcome Research in Scotland study. Drugs Educ Prev Policy. 2006;13(6):537–50.

Article  Google Scholar 

McKeganey N, Morris Z, Neale J, Robertson M. What are drug users looking for when they contact drug services: abstinence or harm reduction? Drugs: education. Prev Policy. 2004;11(5):423–35.

Google Scholar 

Zaaijer ER, Goudriaan AE, Koeter MWJ, Booij J, van den Brink W. Acceptability of extended-release naltrexone by heroin-dependent patients and addiction treatment providers in the Netherlands. Subst Use Misuse. 2016;51(14):1905–11.

PubMed  Article  Google Scholar 

Bigelow GE, Preston KL, Schmittner J, Dong Q, Gastfriend DR. Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: Dose-effects and time-course. Drug Alcohol Depend. 2012;123(1–3):57–65.

CAS  PubMed  Article  Google Scholar 

Sullivan MA, Vosburg SK, Comer SD. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology. 2006;189(1):37–46.

CAS  PubMed  Article  Google Scholar 

Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psych. 2006;63(2):210–8.

CAS  Article  Google Scholar 

Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA Jr, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016;374(13):1232–42.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013;108(9):1628–37.

PubMed  Article  Google Scholar 

Kunøe N, Lobmaier P, Ngo H, Hulse G. Injectable and implantable sustained release naltrexone in the treatment of opioid addiction. Br J Clin Pharmacol. 2014;77(2):264–71.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Latif ZE, Saltyte Benth J, Solli KK, Opheim A, Kunoe N, Krajci P, et al. Anxiety, depression, and insomnia among adults with opioid dependence treated with extended-release naltrexone vs buprenorphine-naloxone: a randomized clinical trial and follow-up study. JAMA Psychiatry. 2018. https://doi.org/10.1001/jamapsychiatry.2018.3537.

Article  PubMed Central  Google Scholar 

Latif ZE, Solli KK, Opheim A, Kunoe N, Benth JS, Krajci P, et al. No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: a 3-month randomized study and 9-month open-treatment follow-up study. Am J Addict. 2019;28(2):77–85.

PubMed  Article  Google Scholar 

Solli KK, Opheim A, Latif ZE, Krajci P, Benth JS, Kunoe N, et al. Adapting treatment length to opioid-dependent individuals’ needs and preferences: a 2-year follow-up to a 1-year study of extended-release naltrexone. Addiction. 2020. https://doi.org/10.1111/add.15378.

Article  PubMed  Google Scholar 

Alkermes. Vivitrol [Internet]. 2021. https://www.alkermes.com/products/vivitrol. Accessed 12 July 2021.

DeFulio A, Everly JJ, Leoutsakos JM, Umbricht A, Fingerhood M, Bigelow GE, et al. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial. Drug Alcohol Depend. 2012;120(1–3):48–54.

CAS  PubMed  Article